Introduction
T-lymphoblastic lymphoma (LL) is a rare lymphoma, which accounts for 2-4% of adult non-Hodgkin's lymphoma (NHL). [1] [2] Lymphoblastic lymphoma is usually diagnosed in young males and is clinically characterized by mediastinal and supradiaphragmatic nodal involvement associated or not with pleural or pericardial effusion. Central nervous system (CNS) involvement is frequent and occurs in approximately 10-20% of cases. The clinical distinction between LL and T-cell acute lymphoblastic leukemia (T-ALL) is based on an arbitrary margin of bone marrow infiltration by 20% of tumor blast cells although these two clinical presentations may be the same disease entity. [2] [3] [4] [5] [6] Owing to this arbitrary distinction between LL and T-ALL, various treatment approaches have been proposed to patients. Acute lymphoblastic leukemia-based chemotherapy or protocols adapted to aggressive NHL followed or not by consolidation with high-dose therapy followed by stem cell therapy have been explored. Results achieved with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or CHOP-like regimens seems to yield poor results with complete remission (CR) rates ranging from 20 to 50% and disease-free survival (DFS) rates from 20 to 50%. 2, 3, 4, [7] [8] [9] Acute lymphoblastic leukemia-type chemotherapy seems to yield better results with CR rates ranging from 70 to 80% and DFS from 30 to 60%. 3, [10] [11] [12] [13] [14] [15] [16] The small number of patients reported for each type of therapy, especially for the ALL-type regimen may account for the lack of a definite consensus regarding LL chemotherapy. Recent progress has been reported in patients treated with intensive ALL-type therapy with survival rates ranging from 40 to 78%. We treated 27 patients with newly diagnosed LL according to an LMT-89 protocol, which is a modified version of the LMT-81 protocol previously reported in pediatric patients. 17 LMT-89 starts with a new induction regimen comprising one course of COP (cyclophosphamide 300 mg/m 2 at D1, vincristine, and prednisone) and two courses of COPADM (cyclophosphamide, vincristine, prednisone, doxorubicin and high-dose methotrexate). The duration of treatment was 1 year plus another 1 year of maintenance therapy with MTX and 6-MP for patients with bone marrow or CNS involvement. We report here our experience in adult patients treated with an adapted LL pediatric protocol. This dose-intensive regimen derived from the LSA2 L2 protocol, combined with intensive induction therapy, reinforced CNS prophylaxis.
Patients and methods

Patients and diagnosis
Between January 1986 and May 2003, 27 adult patients with LL were treated according to the LMT-89 regimen. All patients were required to have a histologically-and/or cytologically proven diagnosis of LL with demonstrated T-LL based on identified T-cell-specific surface markers. Histologic classification was according to either the updated Kiel-classification or the Revised European American Lymphoma Classification. Only one case (a 18-year-old man) with 80% blasts bone marrow involvement and a bulky mediastinal mass had no T-cellspecific surface markers immunophenotype, but only cytological and histological diagnostic of a LL. However, the clinical presentation was highly suggestive of a T-cell lymphoblastic leukemia/lymphoma.
Exclusion criteria were a positive human immunodeficiency virus-1 (HIV-1) status and pretreatment with cytostatic drugs other than corticosteroids and vincristine or more than three courses of CHOP.
The clinical diagnosis and staging included a differential blood cell count in peripheral blood, bone marrow aspiration and smears, serum lactate dehydrogenase (LDH) level. Clinical staging was performed according to the Ann Arbor classification. A chest X-ray and thoracic computed tomography (CT) scan were performed in all patients. Other radiological studies were performed as clinically indicated. Central nervous system involvement was determined through a routine diagnosis or concurrently with administration of CNS prophylaxis. Cerebrospinal fluid was assessed for morphologic and/or immunologic evidence of blasts cells on cytospin preparations, or to detect lymphomatous infiltration with CT or magnetic resonance imaging.
Treatment
Chemotherapy. All patients received a modified LMT-81 regimen (named LMT-89), which was derived from the LSA2 L2 protocol. 17 This new LMT-89 regimen differed from the previous LMT-81 protocol: the induction phase was intensified (Table 1) and preceded by a pre-phase COP regime followed by two identical courses of COPADM. Compared to the LMT-81 protocol, CCNU was removed and five courses of VP16 were added.
The duration of therapy was 12 months for all patients plus another 12 months maintenance therapy with methotrexate (20 mg/m 2 once every week) and purinethol (50 mg/m 2 /day) for patients with bone marrow and/or CNS involvement.
Central nervous system prophylaxis consisted in i.t. therapy during the induction phase as specified in Table 1 followed by five other i.t. methotrexate injections in patients without CNS involvement. Patients with CNS involvement at diagnosis received triple i.t. therapy (including methotrexate, cytarabine and steroids) during induction, consolidation and maintenance therapy. These patients also received three extra courses of highdose methotrexate and two courses of high-dose cytarabine during the consolidation and maintenance phases. Prophylactic cranial irradiation with 24 Gy was scheduled for course 3 of the maintenance phase in patients in CR and with CNS involvement at diagnosis. No intensification with autologous or allogeneic bone marrow transplantation was administered during the first CR.
Response evaluation
Response was evaluated at the end of induction therapy, and at the end of consolidation courses and at completion of therapy, then every 6 months. Response was assessed by clinical examination, peripheral blood and bone marrow aspiration analyses. Responses at mediastinal and other tumor sites were evaluated by CT scans. No biopsy or resection was performed in patients with residual tumor, to exclude active lymphoma. Complete remission was defined as 5% or fewer blast cells in normocellular or hypercellular bone marrow with a granulocyte count X1.1 Â 10 9 /l and a platelet count X100 Â 10 9 /l. The complete disappearance of extra-medullary disease was required for a CR. A partial response (PR) was defined as at least a 50% reduction in nodal (including mediastinal) disease. Unconfirmed complete remission was defined as at least a 75% reduction in nodal disease. Relapse was defined as disease recurrence at any site after achieving a CR and progression was defined as at least a 50% increase in the size of residual disease.
Statistical analysis
The analyses of prognostic factors were based on CR rates, freedom from progression (FFP) and overall survival (OS). The time at risk was the difference between the date of the start of initial treatment and the date of the first failure or the date when censored. Patients with progressive disease on therapy were considered as having a time to progression equal to zero. Freedom from progression and OS curves were estimated using the Kaplan-Meier product-limit method and were compared using the log-rank test. Progression, relapse and death were considered as failures for the analysis of FFP. Factors affecting Abbreviations: COPADM, cyclophosphamide, vincristine, prednisone, doxorubicin and high-dose methotrexate; COP, cyclophosphamide 300 mg/ m 2 at D1, vincristine, and prednisone; Ara-C, cytosine arabinoside; MTX, methotrexate. CPM, cyclophosphamide; VCR, vincristine; CNS, central nervous system; CFR, citrovorum factor; Pred, Prednisone.
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Results
Patient characteristics (Table 2)
The median age of the 27 patients was 31 years (range, 15-57 years). There were 20 male and seven female patients (3:1). The median peripheral blood values were 5.1 Â 10 9 /l (range 135-138) for white blood cells, 121 Â 10 9 /l (range 35-466) for platelets and 13.5 g/dl (range 10.3-16.2) for hemoglobin. Four patients with a predominant mediastinal tumor were included even though they had blast cells in peripheral blood with an increased leukocyte count and thrombocytopenia. Bone marrow infiltration was present in 44% of the patients (n ¼ 12). Five patients had more than 25% of bone marrow infiltration, but with a bulky mediastinal tumor and were then included in this study. In 93% (n ¼ 25) of the patients, a bulky (410 cm) mediastinal tumor and was accompanied by concomitant pleural effusion in 44% (n ¼ 12). Central nervous system involvement at diagnosis was documented in 15% of patients (n ¼ 4). Other tumor sites were lymphadenopathies outside the mediastinum (n ¼ 9), breast (n ¼ 1), skin (n ¼ 1) and Waldeyer's ring (n ¼ 1).
The serum LDH level was available in 25 cases and was elevated in 55% of the patients (n ¼ 14). According to the Ann Arbor classification, three patients had stage I/II and 24 (89%) had advanced disease (stage III/IV).
Treatment results
Of the 27 patients in the study, 20 achieved a CR, three a PR (regression of more than 90% of the mediastinal tumor in all three cases) and four progressed during induction therapy (ORR: 85%). Of the three patients who achieved a PR, two remained in PR with no signs of active disease, 32 and 60 months after induction therapy. With a median follow-up of 81 months, 12/27 (44%) of the patients have remained in first CR (n ¼ 10) or PR (n ¼ 2). Nine patients died of lymphoma (n ¼ 6), toxicityrelated death (n ¼ 2) and one patient died of an unrelated cause (suicide) but with progressive disease. Two patients are still alive with active disease 14 and 20 months after the diagnosis.
The estimated 5-year OS and FFP rate is 63 and 44%, respectively (Figures 1 and 2 ). Sites of relapse or progression could be fully assessed in 14/15 cases. The majority of relapses occurred in the mediastinum (5/14), but recurrent disease was isolated in only 3/14 relapses. Five patients had CNS disease at relapse, which was isolated in two. Two of these five patients had CNS disease at diagnosis. Other sites of relapse/progression were bone marrow in four patients (isolated in one case), the testis and Waldeyer's ring in one case respectively.
Events occurred within 6 months in eight patients (patients with refractory primary disease), between 11 and 14 months after starting therapy in six patients (end of therapy) and 27 months after starting therapy (off-therapy) in only one patient.
Salvage therapy was initiated in 13 patients. Two patients could not receive salvage treatment because of a septic complication following abdominal surgery (n ¼ 1) and a suicide (n ¼ 1). Eight patients received high-dose therapy followed by autologous hematopoietic stem cells after achieving a CR with salvage therapy (n ¼ 6), and allogeneic stem cell transplantation (n ¼ 2). The other patients are still on salvage therapy or were High survival rate with the LMT-89 regimen in LL E Jabbour et al treated with standard ALL therapy (the patient who relapsed offtherapy, 27 months after starting the LMT-89 protocol). Only five of these patients are alive, two on therapy, three in a maintained CR 16 and 22 months after allogeneic bone marrow transplantation and 64 months after ALL standard chemotherapy.
Treatment-related toxicity and morbidity
Fifty-two courses of the new induction chemotherapy were fully assessed for toxicity. With the prephase treatment (COP chemotherapy) and the associated supportive care protocol, none of the patients required dialysis for tumor lysis syndrome. Myelosuppression was the main treatment complication, especially during the COPADM1 and COPADM2 courses. Fiftyseven and 62% of the patients experienced febrile neutropenia requiring intravenous antibiotics, and 12 and 31% required red cells transfusions during the COPADM1 and COPADM2 courses. Platelet transfusion was required in 12 and 8% of the patients during the COPADM1 and COPADM2 courses. Mucositis (grade III/IV) was observed in 8 and 16% during the COPADM1 and COPADM2 courses, respectively. Grade IV infection was observed during 2/26 and 1/26 COPADM1 and COPADM2 courses. No other major therapy-related toxicity was observed.
Prognostic factors for remission duration and survival
The following pretreatment variables were tested for FFP and OS: disease stage, age, serum LDH level and bone marrow involvement. The presence of bulky mediastinal disease or CNS involvement was not assessed (only four patients had CNS disease at diagnosis and 25/27 patients had bulky mediastinal disease). The presence of bone marrow involvement was an adverse prognostic factor for both FFP and OS (Figures 3 and 4) .
Freedom from progression at 36 months (when all the events occurred in our series) was 67724% in patients without bone marrow involvement compared to 21725% in those with bone marrow involvement. Overall survival was 85720% in patients without bone marrow involvement compared to 37730% in those with bone marrow involvement. Age older than 40 and the serum LDH level did not influence outcomes.
Discussion
The natural history of LL is still characterized by rapid disease dissemination involving the bone marrow and CNS. In this study, the great majority of the adult patients with LL were younger than 40 years, with only 3/27 patients older than 50 years, as observed in other recent LL series. The median age at 31 years was very similar to that of the three recent series reported (i.e. 31, 25 and 28 years). 7, 10, 11 The clinical presentation seems to be very comparable between different reports with bulky mediastinal involvement associated or not with other mediastinal organ infiltration (pericardial or pleural). Bulky mediastinal involvement (94%) with pleural effusion in 10/27 (37%) patients in our series is similar to that of other recent series. 7, 10, 11 The frequency of bone marrow and/or CNS infiltration differs slightly between published series, but these differences should be interpreted with caution because of the small number of patients analyzed by each author. Overall, we observed bone marrow involvement and CNS involvement in, respectively, 44 and 15% of patients. On the whole, in the adult patient series mentioned, these clinical characteristics are similar to that observed in childhood LL with males being predominantly affected, mediastinal tumors, and a high-risk of bone marrow and CNS involvement.
Minor differences exist between the population in our series and those reported on by Hoelzer and Thomas. 10, 11 In our series, the proportion of patients with bone marrow and CNS involvement at diagnosis was higher (44 and 15%, respectively). Bone marrow involvement was present in 31 and 15% of cases, and CNS involvement in 0 and 9% in the two series mentioned, 10, 11 respectively. In the recent series reported by the GELA group, CNS and bone marrow involvement was present in 26 and 22% of the patients, respectively. In that series, the GELA group reported on LL patients included in two large studies (LNH 87 and LNH 93 protocols) treated with reinforced CHOP (ACVBP protocol). However, eligibility High survival rate with the LMT-89 regimen in LL E Jabbour et al criteria in one protocol (LNH 93) included patients with LL with no bone marrow and/or CNS involvement. These inclusion criteria concerned half of the patients studied (those in the LNH 93 protocol) and could explain why the incidence of bone marrow infiltration is lower than what we observed in our study group. 7 We observed a CR rate of 75% (20/27 patients), with three additional patients with residual mediastinal infiltration on CTscan evaluation at the end of induction therapy. This yields an ORR of 85% which is similar to that of other studies in adult LL patients. 3, [10] [11] [12] [13] [14] [15] [16] The CR rate with reinforced ACVBP induction therapy adapted to aggressive NHL did not seem to greatly differ from the CR rate observed with ALL-based induction chemotherapy. [2] [3] [4] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] However, long-term disease control and OS seem to be better with ALL-based chemotherapy regimens. With the LMT-89 protocol, we observed a PFS and OS rate of 43 and 65%, respectively, which is similar to the DFS and OS rates reported following treatment with the BFM-ALL and Hyper-CVAD protocols (65 and 51% with the BFM-ALL protocol and 62 and 67% with the Hyper-CVAD, respectively). 10, 11 Five-year OS survival in these three reports was estimated at 50-67%, which seems to be better than the 22% OS recently reported with the ACVBP protocol adapted to aggressive NHL. These recent results strongly suggest that ALL-based chemotherapy should be preferred over classic CHOP or reinforced CHOP chemotherapy in LL.
Two of the three patients with residual mediastinal disease remain free of active lymphoma, 32 and 60 months after starting therapy, which looks similar to what we observed in patients in CR. The prognostic value of CR of mediastinal disease and the role of consolidative mediastinal irradiation in LL is still being debated. The prognostic relevance of residual mediastinal infiltration in patients with bulky disease at presentation has not been assessed in adult patients, but did not seem to influence long-term outcome in childhood. 18 Furthermore, an early randomized prospective trial of mediastinal radiotherapy in childhood LL showed no clinical benefit but increased toxicity following radiotherapy. 19 We did not plan mediastinal irradiation in our protocol and only 3/14 relapses was localized in the mediatinum. Recent data in adult patients did not clearly confirm the role of mediastinal radiotherapy in LL. In the study reported by Hoelzer et al., 10 mediastinal radiotherapy was proposed to the patients (24 Gy), but 7/15 patients who relapsed had a mediastinal relapse despite this consolidative radiotherapy. In the study reported by Thomas et al., 11 2/17 patients replased in the mediastinum after radiotherapy (30-39 Gy), and three progressed before the use of consolidative radiotherapy. In our patients, only two of them relapsed in the mediastinum at 13 and 14 months, and three had progressive disease 3, 3 and 5 months after starting therapy. These results show that few mediastinal relapses are avoided with consolidative radiotherapy, and confirm that only a large randomized study could address this issue.
We assessed the value of previously identified prognostic factors for LL in our patient cohort (bone marrow infiltration, age, LDH serum level, Ann Arbor stage). 3, 4, 8, 10, 13, 16 We found that bone marrow involvement was a strong prognostic factor for OS and FFP, as previously reported. 3 A high serum LDH level was also associated with poor FFP. 3 These prognostic factors were also identified by others, but not by all the authors. 3, 4, 8, [10] [11] [12] [13] These differences could be related to the chemotherapy tested or patient characteristics. Bone marrow involvement was not associated with a poor outcome in the BFM series in which 46% of the patients with bone marrow involvement were alive at 7 years. 10 We only observed a 37% probability of survival at 36 months with a median follow-up of 81 months with the LMT-89 protocol in the same group of patients. These results show that LMT-89 yields poorer results in patients with bone marrow involvement than the BFM protocol. High-dose therapy with autologous or allogeneic bone marrow transplantation has produced encouraging results in LL and may be proposed in this subgroup of patients with a poor survival. 14, [20] [21] [22] In contrast, the LMT-89 protocol is active in adult patients without bone marrow involvement.
In conclusion, our results suggest that bone marrow involvement has a major prognostic value in adult patients treated for LL with this modified LSA2-L2 protocol. In patients without bone marrow involvement, OS is comparable to that reported in childhood series. Other therapeutic options should be proposed to the patients with initial bone marrow infiltration.
